BR112015019721A2 - Polipeptídeo de ligação de ligante isolado ou purificado; molécula de ligação de ligante; conjugado; polinucleotídeo isolado; vetor; célula isolada ou linhagem de células; método para produzir um polipeptídeo de ligação de ligante; composição; método de inibição para neovascularização em um sujeito; método para tratar um sujeito que tem uma doença ocular associada com neovascularização de retina; e uso de uma composição - Google Patents

Polipeptídeo de ligação de ligante isolado ou purificado; molécula de ligação de ligante; conjugado; polinucleotídeo isolado; vetor; célula isolada ou linhagem de células; método para produzir um polipeptídeo de ligação de ligante; composição; método de inibição para neovascularização em um sujeito; método para tratar um sujeito que tem uma doença ocular associada com neovascularização de retina; e uso de uma composição

Info

Publication number
BR112015019721A2
BR112015019721A2 BR112015019721A BR112015019721A BR112015019721A2 BR 112015019721 A2 BR112015019721 A2 BR 112015019721A2 BR 112015019721 A BR112015019721 A BR 112015019721A BR 112015019721 A BR112015019721 A BR 112015019721A BR 112015019721 A2 BR112015019721 A2 BR 112015019721A2
Authority
BR
Brazil
Prior art keywords
ligand
isolated
composition
subject
binding polypeptide
Prior art date
Application number
BR112015019721A
Other languages
English (en)
Other versions
BR112015019721B1 (pt
Inventor
Gerometta Michael
Adams Timothy
Original Assignee
Vegenics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51353421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015019721(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd
Publication of BR112015019721A2 publication Critical patent/BR112015019721A2/pt
Publication of BR112015019721B1 publication Critical patent/BR112015019721B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

POLIPEPTÍDEO DE LIGAÇÃO DE LIGANTE ISOLADO OU PURIFICADO, MOLÉCULA DE LIGAÇÃO DE LIGANTE, POLINUCLEOTÍDEO ISOLADO, VETOR, CÉLULA ISOLADA OU LINHAGEM DE CÉLULAS, MÉTODO PARA PRODUZIR UM POLIPEPTÍDEO DE LIGAÇÃO DE LIGANTE OU UMA MOLÉCULA DE LIGAÇÃO DE LIGANTE, COMPOSIÇÃO, E USOS DE UMA COMPOSIÇÃO. A presente invenção refere-se a moléculas de ligação de ligante e uso das mesmas para modular a angiogênese e/ou a linfangiogênese.
BR112015019721-3A 2013-02-18 2014-02-13 Polipeptídeo de ligação de ligante solúvel isolado ou purificado, molécula de ligação de ligante solúvel, polinucleotídeo isolado ou purificado, vetor, célula hospedeira de microrganismo isolada ou linha celular de microrganismo, método para produzir um polipeptídeo de ligação de ligante ou uma molécula de ligação de ligante, composição e uso de uma composição BR112015019721B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765841P 2013-02-18 2013-02-18
US61/765,841 2013-02-18
US201361782376P 2013-03-14 2013-03-14
US61/782,376 2013-03-14
PCT/AU2014/000114 WO2014124487A1 (en) 2013-02-18 2014-02-13 Ligand binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
BR112015019721A2 true BR112015019721A2 (pt) 2017-08-22
BR112015019721B1 BR112015019721B1 (pt) 2023-08-08

Family

ID=

Also Published As

Publication number Publication date
IL240597B (en) 2020-05-31
EP2956476A1 (en) 2015-12-23
SI2956476T1 (sl) 2020-03-31
HRP20200202T1 (hr) 2020-06-12
AU2014218318B2 (en) 2018-02-15
RU2015137688A (ru) 2017-03-23
AU2014218318A1 (en) 2015-08-20
CA2901226C (en) 2020-11-17
IL240597A0 (en) 2015-09-24
PH12015501785A1 (en) 2015-12-07
LT2956476T (lt) 2020-02-25
JP6408492B2 (ja) 2018-10-17
MX368730B (es) 2019-10-14
US11866739B2 (en) 2024-01-09
DK2956476T3 (da) 2020-02-17
WO2014124487A1 (en) 2014-08-21
EP3693381A1 (en) 2020-08-12
US20170349886A1 (en) 2017-12-07
US10494617B2 (en) 2019-12-03
PT2956476T (pt) 2020-02-21
NZ710658A (en) 2019-12-20
MY170528A (en) 2019-08-09
EP2956476A4 (en) 2016-10-05
JP2019023198A (ja) 2019-02-14
PL2956476T4 (pl) 2020-09-21
RU2699007C2 (ru) 2019-09-02
CA2901226A1 (en) 2014-08-21
CY1122678T1 (el) 2021-03-12
ES2771478T3 (es) 2020-07-06
PL2956476T3 (pl) 2020-09-21
MX2015010499A (es) 2016-03-04
JP2016508372A (ja) 2016-03-22
EP2956476B1 (en) 2019-12-25
US20200165584A1 (en) 2020-05-28
US9745558B2 (en) 2017-08-29
ZA201506186B (en) 2016-11-30
SG11201505940WA (en) 2015-08-28
US20160002612A1 (en) 2016-01-07
RS60026B1 (sr) 2020-04-30
HUE048687T2 (hu) 2020-08-28

Similar Documents

Publication Publication Date Title
WO2019094692A3 (en) Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
GT201700072A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
BR112015009961A2 (pt) imunoglobinas anti-vegf/dll4 com duplo domínio variável e uso destas
PH12014502449A1 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
MX355606B (es) Método in vitro para determinar el potencial miope de un paciente.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112019004353A2 (pt) métodos e vetores para tratar distúrbios do cns
MX2021008663A (es) Anticuerpos mejorados contra il-6.
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
EA201691525A1 (ru) Применение кладрибина для лечения оптиконевромиелита
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
CY1118118T1 (el) Συνεργατικες θεραπειες cannabidiol μαζι με υποθερμια για νευρο-προστασια
BR112015019721A2 (pt) Polipeptídeo de ligação de ligante isolado ou purificado; molécula de ligação de ligante; conjugado; polinucleotídeo isolado; vetor; célula isolada ou linhagem de células; método para produzir um polipeptídeo de ligação de ligante; composição; método de inibição para neovascularização em um sujeito; método para tratar um sujeito que tem uma doença ocular associada com neovascularização de retina; e uso de uma composição

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2014, OBSERVADAS AS CONDICOES LEGAIS